This document is based on a presentation I made at a BABE conference in Baltimore, MD in October 2014. I am Editor in Chief of Journal of Bioequivalence and Bioavailability (BABE) and my field of research is oncology. Many papers cross my desk in process of review and publication in our journal. Why is it, I frequently ask myself, that few if any papers that use bioequivalence and bioavailability as a method to test and ultimately provide new drugs are in the oncology field? On the surface, this seems incongruous. BABE is a beautiful science so it would seem to be natural to use this technology to make new drugs available in a multibillion dollar market. Instead, clinical trials are used in oncology to determine if new products are as good as or better than old products. That is an expensive and time consuming process. Breast cancer for example often takes over a decade to run its course from diagnosis to death or certain cure. From my perspective, this is probably the major reason why, if we are winning the war on cancer, it is not happing rapidly.